今日解读！三星Galaxy Buds 3/Pro新设计曝光：撞脸AirPods，主打ANC功能

三星Galaxy Buds 3/Pro新设计曝光：撞脸AirPods，主打ANC功能

北京，2024年6月14日 - 据外媒报道，三星将于今年7月发布新款真无线耳机Galaxy Buds 3和Buds 3 Pro。近日，有网友曝光了这两款耳机的官方海报，显示其外观设计与此前发布的苹果AirPods Pro 极为相似。

外观设计：撞脸AirPods Pro

根据曝光的海报，Galaxy Buds 3和Buds 3 Pro采用了入耳式设计，耳机主体呈椭圆形，并配备了硅胶耳塞。两款耳机的充电盒也采用了与AirPods Pro相似的椭圆形设计，并支持无线充电。

功能升级：主打ANC功能

据悉，Galaxy Buds 3和Buds 3 Pro将搭载升级版的主动降噪功能（ANC），能够有效降低周围环境噪音，为用户提供更加沉浸式的音频体验。此外，两款耳机还将支持自适应音质功能，能够根据用户所在的环境自动调整音质。

价格及上市时间

目前，三星尚未公布Galaxy Buds 3和Buds 3 Pro的具体价格和上市时间。有分析人士预计，这两款耳机的价格将与上一代产品持平，分别为1499元和1999元。

三星Galaxy Buds系列耳机一直以其出色的音质和佩戴舒适度而受到用户欢迎。此次曝光的Galaxy Buds 3和Buds 3 Pro在外观设计和功能方面均有较大升级，预计将再次受到市场关注。

以下是一些关于三星Galaxy Buds 3和Buds 3 Pro的更多信息：

• Galaxy Buds 3将提供黑色、白色和银色三种颜色选择。
• Galaxy Buds 3 Pro将提供黑色、白色和紫色三种颜色选择。
• 两款耳机均支持蓝牙5.2连接。
• Galaxy Buds 3的电池续航时间约为6小时，充电盒可提供额外12小时续航。
• Galaxy Buds 3 Pro的电池续航时间约为5小时，充电盒可提供额外10小时续航。

媒体联系

三星电子中国有限公司

电话：0755-33878888

网址：https://www.samsung.com.cn/

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.